Alzheimers Drug Reduces Amyloid but Fails to Restore Brain Waste Flow

Researchers found that lecanemab, the Alzheimers drug designed to clear amyloid- plaques, does not improve the brains waste clearance system in the short term. In a three-month study using MRI-based DTI-ALPS imaging, scientists observed no measurable recovery in glymphatic function after treatment.